About ABIO

ARCA biopharma, Inc is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate, Gencaroâ„¢ (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator that is in a clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular systolic dysfunction, or HFREF.
Primary Exchange: NASDAQ
SIC In Vitro & In Vivo Diagnostic Substances
NAICS In-Vitro Diagnostic Substance Manufacturing

ABIO is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VXF Vanguard Extended Market ETF 7.3 B 7.3E+09 3,266 3266 0.0% 0 4 K 3970
ITOT iShares Core S&P Total U.S. Stock Market ETF 22.0 B 2.20343E+10 3,546 3546 0.0% 0 252 252